We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+1.2%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$1.79B
AUM Growth
-$552M
Cap. Flow
+$25.5M
Cap. Flow %
1.42%
Top 10 Hldgs %
44.27%
Holding
146
New
11
Increased
19
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.9M
2
AGEN
Agenus
AGEN
+$27.2M
3
RVMD icon
Revolution Medicines
RVMD
+$21.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.3M
5
VOR icon
Vor Biopharma
VOR
+$11.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$53M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$47.9M
3
BLU
BELLUS Health Inc.
BLU
+$21.4M
4
ONC
BeOne Medicines Ltd
ONC
+$9.17M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$7.88M

Sector Composition

Rank Sector Weight
1 Healthcare 92.03%
2 Consumer Discretionary 3.74%
3 Miscellaneous 3.16%
4 Real Estate 0.39%
5 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
51
Gossamer Bio
GOSS
$63.4M
$7.04M 0.39%
40,583
– –
BEKE icon
52
KE Holdings
BEKE
$17.9B
$6.98M 0.39%
+500,000
New +$6.95M
BHVN icon
53
Biohaven
BHVN
$1.86B
$6.94M 0.39%
+500,000
New +$7.06M
GRTS
54
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$6.4M 0.36%
1,856,194
+1,106,194
+147% +$3.16M
DYN icon
55
Dyne Therapeutics
DYN
$3.34B
$6.08M 0.34%
525,000
– –
ARAV
56
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.04M 0.34%
4,572,515
+3,261,224
+249% +$4.16M
VERV
57
DELISTED
Verve Therapeutics
VERV
$5.8M 0.32%
300,000
-100,000
-25% -$2.65M
ALXO icon
58
ALX Oncology
ALXO
$261M
$5.63M 0.31%
500,000
– –
RNAC icon
59
Cartesian Therapeutics
RNAC
$239M
$5.52M 0.31%
162,773
– –
SYRS
60
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.25M 0.29%
1,463,829
– –
ETNB
61
DELISTED
89bio
ETNB
$5.09M 0.28%
+400,000
New +$3.6M
EQRX
62
DELISTED
EQRx, Inc. Common Stock
EQRX
$4.92M 0.27%
2,000,000
-2,000,000
-50% -$7.88M
SLDB icon
63
Solid Biosciences
SLDB
$897M
$4.89M 0.27%
909,219
+709,219
+355% +$4.65M
AMAM
64
DELISTED
Ambrx Biopharma Inc
AMAM
$4.89M 0.27%
2,152,291
– –
OVID icon
65
Ovid Therapeutics
OVID
$529M
$4.65M 0.26%
2,500,000
– –
AUPH icon
66
Aurinia Pharmaceuticals
AUPH
$2.15B
$4.32M 0.24%
1,000,000
– –
AURA icon
67
Aura Biosciences
AURA
$718M
$4.3M 0.24%
+410,000
New +$5.22M
IMA
68
ImageneBio Inc
IMA
$55.8M
$4.12M 0.23%
129,126
– –
PFTA
69
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
$3.82M 0.21%
380,000
– –
NBTX
70
Nanobiotix
NBTX
$1.79B
$3.67M 0.2%
1,000,000
– –
NBP
71
NovaBridge Biosciences American Depositary Shares
NBP
$184M
$3.55M 0.2%
850,000
– –
ZYME icon
72
Zymeworks
ZYME
$1.86B
$3.54M 0.2%
450,000
– –
MIR icon
73
Mirion Technologies
MIR
$3.81B
$3.31M 0.18%
500,000
– –
TSHA icon
74
Taysha Gene Therapies
TSHA
$1.65B
$3.26M 0.18%
1,440,882
+400,000
+38% +$810K
BDTX icon
75
Black Diamond Therapeutics
BDTX
$113M
$2.96M 0.17%
1,646,517
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2022 Portfolio in Review

As of Q4 2022, Artal Group held 146 positions worth $1.79B, down 24% from $2.34B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q4 2022 filing shows 11 new, 19 increased, 12 reduced and 17 closed positions. Its largest new stake was Revolution Medicines: 1,000,000 shares worth $23.8M. The largest sale was argenx, an estimated $53M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q4 2022 buy was Revolution Medicines: 1,000,000 shares worth $23.8M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $32.9M increase.
  • Artal Group's biggest Q4 2022 reduction was BELLUS Health Inc., cutting an estimated $21.4M.
  • Artal Group fully exited argenx in Q4 2022, selling an estimated $53M.
  • Artal Group's ten largest holdings make up 44% of its $1.79B portfolio in Q4 2022.
  • Artal Group opened 11 new positions and closed 17 in Q4 2022.
  • Artal Group's portfolio value fell 24% quarter-over-quarter to $1.79B.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.